New York- and Alabama-based IN8bio is leveraging gamma-delta (γδ) T cell biology to merge innate and adaptive immune capabilities against cancer. Has some of the early excitement in the cell ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

This new platform aims to expand Gamma-Delta T-cells effectively ... INB-619 targets CD19, a marker found on B cells involved in leukemias, lymphomas, and autoimmune conditions.

(Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced today a poster presentation on its ...

The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in leukemias, lymphomas, and autoimmune diseases. In preclinical models, INB-619 ...

White blood cells in the GI tract known as intraepithelial lymphocytes express the gamma delta T cell receptor (gamma delta IELs), which prevent infection and provide surveillance for the ...

The Abingworth-backed biotech is developing therapies based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role in a host of immune responses and ...

GammaDelta’s drug platform is based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role to many types of immune responses and immunopathology.